Dick's questions to Moderna Inc (MRNA) leadership • Q1 2025
Question
Dick, on for Myles Minter, asked if the source of the GBS case in the norovirus trial was identified and how Moderna is comparing its intismaran T cell clone data to that of competitors like BioNTech.
Answer
President Stephen Hoge confirmed the clinical hold on the norovirus trial was lifted but stated that causality for the rare GBS case may never be known, as such cases occur in the background population. Regarding intismaran, he could not comment on competitor methods but expressed encouragement with Moderna's own TCR clonality data, which supports the existing efficacy evidence.